ArthroCare Announces Two Upcoming Presentations; CEO to Present During UBS Global Life Sciences Conference and Sidoti & Co. San Francisco Conference.

AUSTIN, Texas -- ArthroCare(R) Corp. (NASDAQ:ARTC), a multi-business medical device company that develops minimally invasive surgical products, announced today details surrounding two upcoming presentations.

UBS Global Life Sciences Conference

ArthroCare will present during the 2005 UBS Global Life Sciences Conference in New York. Michael Baker, president and chief executive officer for ArthroCare, will deliver the business presentation. Further details include:

--Date: Tues., Sept. 27, 2005

--Time: 3:00 p.m. ET

--Location: Grand Hyatt New York / Park Ave. at Grand Central Terminal / New York

The presentation will be Webcast live and can be accessed on ArthroCare's Web site at www.arthrocare.com or at event.streamx.us/event/20050926. The Web cast will remain available until Oct. 29, 2005.

Sidoti & Co. San Francisco Conference

ArthroCare will present during the fourth annual Sidoti & Co. San Francisco Conference. Baker will deliver the business presentation. Further details include:

--Date: Fri., Sept. 30, 2005

--Time: 3:15 p.m. PT

--Location: The Ritz-Carlton, San Francisco / 600 Stockton at California St. / San Francisco

Sidoti & Co. will not Webcast presentations at its San Francisco Conference.

ABOUT ARTHROCARE

Founded in 1993, ArthroCare Corp. (www.arthrocare.com) is a highly innovative, multi-business medical device company that develops, manufactures and markets minimally invasive surgical products. With these products, ArthroCare targets a multi-billion dollar market opportunity across several medical specialties, significantly improving existing surgical procedures and enabling new, minimally invasive procedures. Many of ArthroCare's products are based on its patented Coblation technology, which uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue -- minimizing damage to healthy tissue. Used in more than four million surgeries worldwide, Coblation-based devices have been developed and marketed for sports medicine; spine/neurologic; ear, nose and throat (ENT); cosmetic; urologic and gynecologic procedures. ArthroCare also has added a number of novel technologies to its portfolio, including Opus Medical sports medicine, Parallax spine and Applied Therapeutics ENT products, to complement Coblation within key indications.

SAFE HARBOR STATEMENTS

Except for historical information, this press release includes forward-looking statements. These statements include, but are not limited to, the company's stated business outlook for fiscal 2005 and 2006, continued strength of the company's fundamental position, the strength of the company's technology, the company's belief that strategic moves will enhance achievement of the company's long term potential, the potential and expected rate of growth of new businesses, continued success of product diversification efforts, and other statements that involve risks and uncertainties. These risks and uncertainties include, but are not limited to the uncertainty of success of the company's non-arthroscopic products, competitive risk, uncertainty of the success of strategic business alliances, uncertainty over reimbursement, need for governmental clearances or approvals before selling products, the uncertainty of protecting the company's patent position, and any changes in financial results from completion of year-end audit activities. These and other risks and uncertainties are detailed from time to time in the company's Securities and Exchange Commission filings, including ArthroCare's Form 10-Q for the quarter ended June 30, 2005 and Form 10-K for the year ended Dec. 31, 2004. Forward-looking statements are indicated by words or phrases such as "anticipates," "estimates," "projects," "believes," "intends," "expects," and similar words and phrases. Actual results may differ materially from management expectations.